ALNY: Alnylam Pharmaceuticals Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 1 sales totaling $399K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-02 | Supran Bryan | Officer | $399K |
Institutional ownership (Q2 2026)
795 institutions reported holding $37.92B of Alnylam Pharmaceuticals Inc on Form 13F (794 the quarter before). 82 opened a new position and 80 sold out. Shares held by institutions: +2%.
| Largest holders | Shares | Value |
|---|---|---|
| FMR LLC | 15,023,962 | $4.52B |
| Capital World Investors | 11,144,846 | $3.35B |
| BlackRock, Inc. | 10,907,675 | $3.28B |
| Capital Research Global Investors | 9,750,699 | $2.94B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,538,390 | $1.97B |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,029,478 | $1.82B |
| Invesco Ltd. | 3,754,318 | $1.13B |
| STATE STREET CORP | 3,555,689 | $1.07B |
| GEODE CAPITAL MANAGEMENT, LLC | 2,635,840 | $791.35M |
| JPMORGAN CHASE & CO | 2,675,517 | $785.32M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.